Effexor (R) XR achieved long-term remission in 67 percent of recurring depression patients

Philadelphia, PA, May 21, 2002 Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), announced today that 67 percent of patients with depression maintained remission of their symptoms, a critical milestone on the way to recovering from their disease, after a year of therapy with the antidepressant Effexor XR (venlafaxine HCl), according to data from a multicenter trial presented at the American Psychiatric Associations (APA) annual meeting. For patients with recurrent major depression who achieve remission, continuing with Effexor XR is particularly effective in maintaining that remission, said lead investigator Charles Nemeroff, M.D., Ph.D., Reunette W. Harris Professor and Chairman of the Department of Psychiatry and Behavioral Sciences at Emory University School of Medicine. Given these data, people suffering from recurrent depression and their health care providers can aim to virtually eliminate depression symptoms, rather than settle for a mere response to treatment. All of the patients had previously achieved remission during six months of Effexor XR therapy, in the first stage of the study. They were then asked to participate in a second, 12-month double-blind placebo-substitution phase in which neither the investigators nor the patients knew who received the drug or a placebo until the end of the trial.

During the open-label first stage of the study, 43 percent of patients reached remission after eight weeks of therapy; this rose to 53 percent at the end of six months. The researchers defined remission as a score of seven or less on the 17-item Hamilton Rating Scale for Depression (HAM-D17), a standard depression rating scale. During the second stage of the study, investigators found a significantly higher percentage of patients maintained their remission among the 106 members of the Effexor XR group compared to the 107 participants receiving a placebo at each monthly observation point after the first month of treatment. At the end of 12

Contact: Doug Petkus, Wyeth Pharmaceuticals
Porter Novelli

Page: 1 2 3

Related medicine news :

1. Landmark antidepressant analysis demonstrated significant efficacy of Effexor®/Effexor XR
2. Highest known catalytic rate for superoxide dismutation achieved
3. Donor age has no affect on long-term liver transplant survival
4. Short-term effects of spit tobacco suggest long-term health risks
5. Even mild depression increases long-term mortality in heart failure
6. New theory chalenges current view of how brain stores long-term memory
7. Study shows long-term use of NSAIDs causes severe intestinal damage
8. Researchers find circulating tumor cells in long-term cancer survivors
9. New study shows early ritalin may cause long-term effects on the brain
10. No long-term harm from repeated prenatal ultrasound examination
11. Study identifies factors associated with long-term opioid treatment of veteran patients

Post Your Comments:

(Date:9/3/2020)... ... September 03, 2020 , ... ... be the focus of Fall 2020 Virtual Conference, a two-day virtual event for ... Enterprise Imaging & Beyond" is the follow-up to AuntMinnie.com's successful virtual event in ...
(Date:9/2/2020)... WASHINGTON, Pa. (PRWEB) , ... September 02, 2020 ... ... development of enterprise software for healthcare payers administering Medicare Advantage and Special Needs ... Duals Online presented by America’s Health Insurance Plans (AHIP). RAM is supporting the ...
(Date:9/1/2020)... ... September 01, 2020 , ... As fall and winter ... Cohn Health Institute has taken this time to expand and grow into ... 30th Anniversary, the Cohn Health Institute will be relaunching its brand new website, expanding ...
(Date:8/31/2020)... (PRWEB) , ... August 31, 2020 , ... Just found out your dear friend has ... heartbreaking when your friend or family member shares their diagnosis. Once the shock wears off, ... say the wrong thing? What are the best ways to help? Words are failing me. ...
(Date:8/31/2020)... (PRWEB) , ... August 31, 2020 , ... ... of innovative higher-learning opportunities through high-quality, career-relevant, and affordable online education – is ... Psychology . , Among the first of its kind in the nation, ...
Breaking Medicine News(10 mins):
(Date:8/27/2020)... ... 27, 2020 , ... Austin Oral Surgery – an oral and maxillofacial surgery ... Szalay, DDS, MD, has joined the practice. An accomplished oral and maxillofacial surgeon, Dr. ... is scheduled to open this fall. The new office is slated for 1601 E. ...
(Date:8/27/2020)... ... August 27, 2020 , ... Bridge To A Cure Foundation announces the appointment ... and pediatric neuro-oncologist who serves on the Board of Directors at The Preston Robert ... Medical School. , Internationally recognized, Dr. Friedman is a widely published author of more ...
(Date:8/26/2020)... ... August 26, 2020 , ... ... BioPharma Services, Laboratory Testing division, expands its technology footprint with the addition ... Cytometry platforms available. With industry-leading biomarker solutions, complemented with traditional ligand-binding assays ...
Breaking Medicine Technology:
Cached News: